A Reliable Research Partner in Life Science and Medicine

Recombinant Human TREML2/TLT2 Protein (His Tag)

Catalog Number: PKSH031041

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description

Species Human

Source HEK293 Cells-derived Human TREML2/TLT2 protein Met 1-Ser 268, with an C-

terminal His

Calculated MW 28.5 kDa Observed MW 55-60 kDa Accession NP 079083.2

Not validated for activity **Bio-activity**

Properties

> 95 % as determined by reducing SDS-PAGE. **Purity**

Endotoxin < 1.0 EU per µg of the protein as determined by the LAL method.

Storage Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80

°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of

reconstituted samples are stable at < -20°C for 3 months.

This product is provided as lyophilized powder which is shipped with ice packs. Shipping

Lyophilized from sterile PBS, pH 7.4 **Formulation**


Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants

before lyophilization.

Please refer to the specific buffer information in the printed manual.

Please refer to the printed manual for detailed information. Reconstitution

Data



> 95 % as determined by reducing SDS-PAGE.

Background

Elabscience Bionovation Inc.

A Reliable Research Partner in Life Science and Medicine

Elabscience®

Trem-like transcript 2 protein, also known as Triggering receptor expressed on myeloid cells-like protein 2, TREML2 and TLT2, is a single-pass type I membrane protein which contains one Ig-like V-type (immunoglobulin-like) domain.

TREML2 is detected in cultured B cells, T cell leukemia and monocyte leukemia. TREML2 is expressed constitutively on CD8 T-cells and induced on CD4 T-cells after activation. TREML2 is a cell surface receptor that may play a role in the innate and adaptive immune response. TREML2 acts as a counter-receptor for CD276 and interaction with CD276 on T-cells enhances T-cell activation. Murine B7-H3 specifically bound to Triggering receptor expressed on myeloid cells (TREM)-like transcript 2 (TLT-2, TREML2). TREML2 was expressed on CD8(+) T cells constitutively and on activated CD4(+) T cells. Stimulation with B7-H3 transfectants preferentially up-regulated the proliferation and IFN-gamma production of CD8(+) T cells. Transduction of TREML2 into T cells resulted in enhanced IL-2 and IFN-gamma production via interactions with B7-H3. There maybe a direct interaction between B7-H3 and TREML2 that preferentially enhances CD8(+) T cell activation.

Toll-free: 1-888-852-8623 Web:www.elabscience.com Fax: 1-832-243-6017